Clinician Use of Clover Assistant is Associated with Earlier Identification and Management of Diabetes
12 Outubro 2023 - 9:30AM
Today, Clover Health (“Clover” or “the Company”) issued an analysis
titled Clover Assistant Use and Diagnosis, Treatment, and
Progression of Diabetes, which examines the association between use
of the company’s flagship technology product, Clover Assistant
(“CA”), and earlier physician identification and management of
diabetes.
“Early diagnosis and treatment of diabetes in the Medicare
population is essential for preventing complications, improving
overall health and well being, and reducing the economic burden
associated with the condition,” said Dr. Kumar Dharmarajan, Chief
Medical Officer of Clover Assistant. “Our findings demonstrate that
use of Clover Assistant is associated with not only earlier
diabetes diagnosis and treatment with oral diabetes medications,
but also lower blood sugar, insulin use, and hypoglycemia, a major
insulin-related complication.”
“As a technology platform, Clover Assistant is built to improve
care in a scalable way by synthesizing large volumes of data from
disparate sources and surfacing key clinical insights to clinicians
when they are with their patients,” said Peter Loscutoff, Data
Science Fellow at Clover Health. “Similar to the findings in our
recently published analysis of the relationship between Clover
Assistant use and the diagnosis and progression of chronic kidney
disease, we found that clinicians using our technology – as
compared to those who do not – are more effective at diagnosing and
managing diabetes earlier, resulting in improved patient
outcomes.”
“It’s definitely helpful to have the A1c data in Clover
Assistant. I’ll see patients that are brand new to me and will pull
up Clover Assistant and be shocked - this patient is telling me
that they have no medical problems and are not on any specific
medications that would imply they do, but CA will show otherwise,”
said Dr. Krystle Chua of AKKC Medicine, in Haledon, New Jersey.
“The diabetes comorbidities that CA lists are also important to
address. For example, I appreciate seeing evidence of peripheral
arterial disease, because that reminds me to get the patient in for
additional screening tests. Ophthalmology data is also beneficial
because it reminds me to make sure that the patient is up to date
on his/her retinopathy screening or follow up exams for their
diabetes. These are conditions worth screening for and catching
early because the complications they cause can be
debilitating.”
The full results of the diabetes analysis are available on
Clover’s website: www.cloverhealth.com/clinicalcare/diabetes
About Clover Health:Clover Health (Nasdaq:
CLOV) is a physician enablement company committed to bringing
access to great healthcare to everyone on Medicare. This includes a
health equity-based focus on seniors who have historically lacked
access to affordable, high-quality healthcare. Our strategy is
powered by our software platform, Clover Assistant, which is
designed to aggregate patient data from across the healthcare
ecosystem to support clinical decision-making and improve health
outcomes through the early identification and management of chronic
disease. We operate two distinct lines of business: Insurance and
Non-Insurance. Through our Insurance line of business, we provide
PPO and HMO Medicare Advantage plans in several states, with a
differentiated focus on our flagship wide-network, high-choice PPO
plans. Our Non-Insurance line of business similarly aims to reduce
cost-of-care while enhancing the quality of care for patients
enrolled in Original Medicare.
Press Contact:Andrew
Still-Baxterpress@cloverhealth.com
Investor Relations Contact:Ryan
Schmidtinvestors@cloverhealth.com
Clover Health Investments (NASDAQ:CLOV)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Clover Health Investments (NASDAQ:CLOV)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024